Video

Urologists discuss why kidney stones should be considered “a mainstream public health problem”

Author(s):

Urology Times staff

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

Nevo is chief of endourology at University Hospitals Urology Institute and is an assistant professor of urology at Case Western Reserve University School of Medicine in Cleveland, Ohio. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, Cleveland, Ohio.

Related Videos
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
Related Content
FDA grants de novo clearance to Stone Clear device
November 13th 2024

FDA grants de novo clearance to Stone Clear device

Hannah Clarke
"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse
August 29th 2024

Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse

Hannah Clarke
In total, 8 of 40 patients who underwent ultrasonic propulsion experienced relapse, compared with 21 of 42 patients who underwent observation.
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
Trial launches of gene editing therapy for primary hyperoxaluria type 1
August 24th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1

Hannah Clarke
In total, the trial plans to enroll 7 patients with PH1 through a single center in China.
Data suggest Break Wave lithotripsy is safe, effective for urolithiasis
August 21st 2024

Data suggest Break Wave lithotripsy is safe, effective for urolithiasis

Hannah Clarke
Any stone fragmentation was achieved in 88% of patients.
© 2024 MJH Life Sciences

All rights reserved.